Everolimus Tab. not checked
FollowEvery change as it happens, and a Monday email
Trials
19 active
23 in total · 21 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Up to 1.5g BID(total 3g daily), PO - Check the blood concentration of Everolimus at each visit”In the company’s words, NCT06942156 on ClinicalTrials.gov
- Tested for
- Heart Transplant
- Main trialPhase 4
- “The purpose of this study is to evaluate the efficacy and safety of lower dose calcineurin inhibitors (CNI) in combination with Everolimus in Korean heart transplant recipients.”In the company’s words, NCT06942156 on ClinicalTrials.gov
- Other names
- CertiroBell Tab. · Everolimus
Coming up1
- Dec 2030Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials23
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Not yet recruiting | Dec 2030 | Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea | |
| Phase 4Completed | 24 Jul 2024 | Efficacy and Safety of Everolimus Versus Mycophenolate Mofetil in Liver Transplant Recipients. | |
| Phase 3Authorised | not given | Efficacy, safety and patient-reported outcomes of peptide receptor radionuclide therapy with 177Lu-edotreotide compared to everolimus in somatostatin receptor positive neuroendocrine tumors of the lung and thymus. The LEVEL trial | |
| Phase 3/4Ended | not given | Prospective Randomized trial of Everolimus replacing MMF/MP Acid by the RECOVAC consortium to increase VACcine response in kidney transplant patients | |
| Phase 2Authorised | not given | Individualized everolimus therapy in metastatic breast cancer | |
| Phase 3Authorised | not given | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication: BIOMEDE 2.0 | |
| Phase 2Ended | not given | Targeting mTOR with everolimus and/or physical training for preventing postmenopausal bone loss and accelerated skeletal aging. The RapaLoad study. | |
| Phase 2Authorised | not given | Evaluation of the addition of Everolimus to 177Lu-DOTATATE in the treatment of grades 2 and 3 refractory meningioma: a phase IIb clinical trial | |
| Phase 4Authorised | not given | zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric randomized clinical study with intervention | |
| Phase 2Authorised | not given | Repurposing Everolimus to enhance musculoskeletal Vitality and Ageing in The Elderly (RENOVATE) | |
| Phase 2Authorised | not given | An open-label single arm interventional phase 2 study to investigate outcome of individualized treatment based on pharmacogenomic profiling and ex vivo drug sensitivity testing of patient-derived organoids in patients with metastatic colorectal cancer | |
| Phase 3Authorised | not given | A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors - The ADELA study- | |
| Phase 4Authorised | not given | Efficiency of everolimus for the treatment of kidney transplanted patients presenting a missing self-induced NK-mediated rejection (STARR) | |
| Phase 1/2Authorised | not given | AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | |
| Phase 3Authorised | not given | UNIRAD : Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease | |
| Phase 4Ended | not given | The OPTIMIzE study;OPen label multicenter randomized Trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients. | |
| Phase 2Authorised | not given | A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL | |
| Phase 4Authorised | not given | Safety and efficacy of steering of immunosuppression based on BKPyV-specific T cells in case of BK Polyomavirus (BKPyV) DNAe- mia after kidney transplantation | |
| Phase 2Authorised | not given | Resistance training and rapamycin to enhance bone formation in postmenopausal women (STRONGBONE) | |
| Phase 4Authorised | not given | Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy _ POG | |
| Phase 1Authorised | not given | Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma; MEDWAY | |
| Phase 3Authorised | not given | Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe year AfTer lIver transplantatiON (ALTERNATION) – a randomized, prospective, multicenter, open-label, controlled phase III trial | |
| Phase 4Authorised | not given | HORUS-Cytomegalovirus Open Proof-of-concept Exploratory trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026